Published in Gene Therapy Weekly, December 20th, 2001
Pursuant to an existing Cooperative Research and Development Agreement (CRADA), the NCI has solicited new proposals from investigators to study Genasense in combination with standard anticancer therapy. Specific trials were requested in a broad group of diseases, including cancer of the prostate, breast, lung, colon, bladder, ovary, uterus, kidney and pancreas, and in Merkel cell tumor and non-Hodgkin lymphoma. Under the CRADA terms, NCI and Genta will jointly review and approve the initiation of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly